REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 5, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On September 4, 2025, Nyxoah rec...
Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 20...
Nyxoah's Genio system received FDA approval, unlocking access to the US market and validating its innovative, patient-friendly OSA treatment. Recent earnings show strong revenue growth but continued losses as Nyxoah invests heavily in US commercialization and expansion efforts. Key risks include rising debt, dilution, ongoing patent litigation, and high competition, but GLP-1 drugs pose less th...
Nyxoah SA (NASDAQ:NYXH ) Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO & Executive Director Pearson Dennis - Corporate Participant Conference Call Participants David Kenneth Rescott - Robert W. Baird & Co. Incorporated, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated,...
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstruc...
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for th...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.